- The study was designed as a nonrandomized, multistage, open-label, multicenter evaluation of ELZONRIS as monotherapy in patients with BPDCN, regardless of whether they had received previous treatment1,2
- FDA approval of ELZONRIS was based on the efficacy and safety observed in 13 treatment-naive patients in the pivotal cohort and 15 previously treated patients from other cohorts3,4
- Following FDA approval, 40 additional patients (36 treatment-naive, 4 previously treated) were enrolled in a continued access cohort3,5
The primary outcome was CR/CRc3*†
Initial analysis
- Efficacy was confirmed in the pivotal cohort of 13 treatment-naive patients1,2
- Median follow-up was ~2 years3
Long-term analysis
- The long-term analysis included all 44 patients from the initial analysis, as well as 40 others enrolled in the continued access cohort1,3,5
- 65 treatment-naive patients and 19 previously treated patients were efficacy evaluable1
- Patients with CR/CRc received ELZONRIS until disease progression, unacceptable toxicity, or allogeneic (allo)/autologous (auto) SCT2,4
- Median follow-up was ~3 years1
See the long-term study design
*Complete response (CR) criteria: normalization of blast percentage (≤5%) in the bone marrow; normalization of neutrophil count (≥1000/μL) and platelet count (≥100,000/μL) in the peripheral blood; absence of leukemic blasts in the peripheral blood; 100% clearance of all skin lesions from baseline; no new lesions in patients without lesions at baseline; regression of nodal masses to normal size on CT; no palpable nodules on the spleen or liver.2
†Clinical complete response with minimal residual skin abnormality (CRc) criteria: marked clearance of all skin lesions from baseline; residual hyperpigmentation or abnormality with BPDCN identified on biopsy (or no biopsy performed).2
‡Dosing period may be extended for dose delays up to day 10 of the cycle.4
Baseline patient characteristics (initial analysis)
Treatment-naive patients2,4
Characteristics | Pivotal cohort (n=13) |
Other cohorts (n=16) |
Total§ (n=29) |
---|---|---|---|
Male, % (n) | 84.6% (11) | 75.0% (12) | 79.3% (23) |
Female, % (n) | 15.4% (2) | 25.0% (4) | 20.7% (6) |
Median age | (min, max)65.0 (22, 84) | 67.5 (28, 84) | 67.0 (22, 84) |
ECOG PS, % (n) | |||
0 | 61.5% (8) | 43.8% (7) | 51.7% (15) |
1 | 38.5% (5) | 56.3% (9) | 48.3% (14) |
BPDCN, % (n) | |||
Skin | 100.0% (13) | 93.8% (15) | 96.6% (28) |
Bone marrow | 53.8% (7) | 43.8% (7) | 48.3% (14) |
Peripheral blood | 23.1% (3) | 25.0% (4) | 24.1% (7) |
Lymph nodes | 46.2% (6) | 43.8% (7) | 44.8% (13) |
Visceral | 15.4% (2) | 12.5% (2) | 13.8% (4) |
Previously treated patients2-4
Characteristics | Previously treated patients | (n=15)
---|---|
Male, % (n) | 86.7% (13) |
Female, % (n) | 13.3% (2) |
Median age | (min, max)72 (44, 80) |
ECOG PS, % (n) | |
0 | 33.3% (5) |
1 | 66.7% (10) |
BPDCN, % (n) | |
Skin | 86.7% (13) |
Bone marrow | 60.0% (9) |
Peripheral blood | 6.7% (1) |
Lymph nodes | 53.3% (8) |
Visceral | 26.7% (4) |
Prior treatments, % (n) | |
Radiation therapy | 33.3% (5) |
Stem cell transplantation | 26.7% (4) |
Previous lines of therapy: Previously treated patients3
Number of lines | Previously treated patients |
---|---|
1 | 60% (9) |
2-3 | 27% (4) |
≥4 | 13% (2) |
§Total population (n=29) includes patients from the pivotal cohort (n=13).2,3
BPDCN, blastic plasmacytoid dendritic cell neoplasm; CT, computed tomography; ECOG PS, Eastern Cooperative Oncology Group performance status; SCT, stem cell transplantation.
Explore a treatment with durable efficacy in treatment-naive patients
- References:
- Pemmaraju N, et al. Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2022;40(26):3032-3036.
- Data on file. Stemline Therapeutics, Inc.
- Pemmaraju N, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628-1637.
- ELZONRIS [prescribing information]. New York, NY: Stemline Therapeutics, Inc.; November 2022.
- Pemmaraju N, et al. Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2022;40(26):3032-3036 [supplementary appendix].